<DOC>
	<DOCNO>NCT00002586</DOCNO>
	<brief_summary>RATIONALE : 13 Cis retinoic acid may prevent development cancer cell . PURPOSE : Randomized double-blinded phase II trial study effectiveness 13-cis retinoic acid without vitamin E chemoprevention observation cancer person high risk develop lung cancer .</brief_summary>
	<brief_title>13-Cis Retinoic Acid With Without Vitamin E Prevention Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine alpha tocopherol reduce toxicity low dose 13-cis retinoic acid administer one year . - To access adequacy collect specimens study intermediate endpoint marker . - establish depository biologic specimens future study new biomarkers . - Arm 1 : Patients receive oral 13-cis retinoic acid daily . - Arm 2 : Patients receive oral 13-cis retinoic acid oral vitamin E daily . - Arm 3 : Patients undergo observation . Treatment continue arm I II 1 year absence unacceptable toxicity . Patients follow annually 2 year . PROJECTED ACCRUAL : A total 100 patient ( 33 Arm 1 , 33 Arm 2 , 34 Arm 3 ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . Patients identified Tissue Procurement/Screening Project mild , moderate severe dysplasia , Ca In situ OR surgically cure patient head neck cancer find mild atypia great stag bronchoscopy . ( This include carcinoma situ ) . Also eligible patient Stage I II nonsmall cell lung cancer disease free great 36 month . 2 . Patients must least 30 pack year smoke history . 3 . Patients must current smoker exsmoker smoke least 6 month . 4 . Patients must peripheral granulocyte count &gt; 1500 platelet count &gt; 150,000 . 5 . Patients must adequate hepatic function bilirubin &lt; 1.5 mg % SGPT &lt; 4 time institutional upper limit normal . 6 . Patients must adequate renal function serum creatinine &lt; 1.5 mg % . 7 . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . 1 . Patients must current past history cancer within past 5 year exception surgically cure head neck cancer surgically cure Stage I II lung cancer &gt; 36 month diagnosis skin cancer situ cancer . 2 . Patients must serious intercurrent illness include insulin dependent diabetes mellitus hypercholesterolemia ( &gt; 239mg/dl ) / hypertriglyceridemia ( &gt; 149mg/dl ) . 3 . Patients must evidence clinically active coronary artery disease include myocardial infarction within 6 week , chest pain poorly control congestive heart failure serious medical condition , would preclude patient undergoing bronchoscopy . 4 . Patients must cardiac dysrhythmia potentially life threaten ventricular tachycardia , multifocal premature ventricular contraction supraventricular tachycardia rapid ventricular response . Well control atrial fibrillation rare ( &lt; 2/minute ) premature ventricular contraction exclusionary 5 . Chest xray must show evidence tumor . 6 . Patients must take vitamin A E supplement 7 . Patients must take tetracycline minocycline . 8 . Patients prior chemotherapy radiation therapy . 9 . Women pregnant ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>